Industry news

Australia's new PM looks to biotech for a boom as mining-led growth wanes, WSJ says

EJ Lane / FeircePharmaAsia

R&D tax incentives combined with a former investment banker as the country's new prime minister could see steady growth in biotech in Australia gain momentum, the Wall Street Journal reports.

Novartis hit by China, emerging market slowdown-CEO on CNBC

John Miller / Reuters

Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC.

Big Pharma Stock Unappreciated by Analysts Is a Top Performer

Oliver Renick Melissa Mittelman Drew Armstrong / Bloomberg Business

SVB brushes off those nagging worries about a biotech bubble

John Carroll / FierceBiotech

Market turbulence around the world hasn't shaken the confidence of Silicon Valley Bank's analysts in the driving force behind a three-year stretch of biotech IPOs. In their recent half-year review, SVB says they're sticking with a prediction of 45 to 55 biotech IPOs for the year as investors continue to hunt down some big returns in a market where safe havens still don't pay very well.

Why launching a new drug first is key

Gregory Phillips / World Economic Forum

Lagging behind in launching new medicines means a much smaller market share for pharmaceutical companies — even if they spend just as much on advertising, according to new research from Duke University’s Fuqua School of Business.

How much is first-to-market worth? There's a formula for that

Tracy Staton / Fierce Pharma Marketing

Researchers at Duke University's Fuqua School of Business not only quantified the gains that await first-to-market meds, but came up with a tool to predict success--or lack of it--for new drugs based on when they hit the market and how much they spend on ads.

Gallup charts another big slide for pharma's public image

Tracy Staton / Fierce Pharma Marketing

Another day, another survey showing that pharma's reputation stinks in the U.S. This time, though, the survey-taker is Gallup, and while the industry's rating is down significantly from last year, it's not nearly as bad as it was 10 years ago.

How Russia Should Change Its Healthcare System?

Vitaly Omelyanovsky / EconoMonitor

Over the last twenty years, Russia has significantly changed the way it finances healthcare. Before the collapse of the USSR, the nation’s healthcare system had been supported from the budget. June of 1991 marked the birth of health insurance in the country: In that month, the Russian parliament adopted a new law on medical insurance. In 1993, the government established one federal and eighty-nine regional funds for general medical insurance financed by employer contributions. 

Putin: Up to 90% of Russia's pharmaceuticals to be home-made by 2018

Balita Organization

Russia needs to produce up to 90 percent of its own pharmaceuticals by 2018, Russian President Vladimir Putin said Monday. The Russian president noted that the pharmaceuticals are a high income business and called for investments to develop the country’s pharmaceutical industry.

Researchers in Central Russia develop proton system to fight cancer

Marchmont Innovation News

Scientists at the Tsyb Medical Radiology Research Center in Obninsk, in the Kaluga region in Central Russia, are developing a new proton accelerator which is expected to dramatically improve the efficacy of cancer treatment, portal Hi-tech.mail.ru reported.  Similar equipment is successfully used in other countries as well; however, it is way over 10 times more expensive than what the Obninsk researchers are putting together, the source underscored: $61.5m in Germany, for example, vs. $4.6m in the Kaluga region.